Neurology
90, e1889-e1897
DOI: 10.1212/wnl.0000000000005550

Citation Report

#	Article	IF	Citations
1	SAR228810: an antibody for protofibrillar amyloid Î² peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). Alzheimer's Research and Therapy, 2018, 10, 117.	3.0	14
2	Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâ€™s disease (BLAZE). Alzheimer's Research and Therapy, 2018, 10, 96.	3.0	109
3	Grasping at straws: the failure of solanezumab to modify mild Alzheimerâ€™s disease. Expert Opinion on Biological Therapy, 2018, 18, 1189-1192.	1.4	17
4	Recent advancements toward therapeutic vaccines against Alzheimerâ€™s disease. Expert Review of Vaccines, 2018, 17, 707-721.	2.0	46
5	Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases. CNS Drugs, 2019, 33, 883-904.	2.7	23
6	Targeting the transferrin receptor for brain drug delivery. Progress in Neurobiology, 2019, 181, 101665.	2.8	204
7	Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings. Journal of Alzheimer's Disease Reports, 2019, 3, 179-218.	1.2	16
8	Alzheimer's disease drug development pipeline: 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 272-293.	1.8	546
9	A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimerâ€™s Disease. Scientific Reports, 2019, 9, 9870.	1.6	35
10	Anti-AÎ² Antibodies and Cerebral Amyloid Angiopathy Complications. Frontiers in Immunology, 2019, 10, 1534.	2.2	25
11	Applications of Quantitative Systems Pharmacology in Modelâ€Informed Drug Discovery: Perspective on Impact and Opportunities. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 777-791.	1.3	45
12	Current Landscape of Late-Phase Clinical Trials for Alzheimerâ€™s Disease: Comparing Regional Variation Between Subjects in Japan and North America. Pharmaceutical Medicine, 2019, 33, 511-518.	1.0	2
13	Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2019, 3, 77-94.	1.2	4
14	Drug Development for Alzheimerâ€™s Disease: Microglia Induced Neuroinflammation as a Target?. International Journal of Molecular Sciences, 2019, 20, 558.	1.8	99
15	A short perspective on the long road to effective treatments for Alzheimer's disease. British Journal of Pharmacology, 2019, 176, 3636-3648.	2.7	17
16	Alzheimerâ€™s disease: future drug development and the blood-brain barrier. Expert Opinion on Investigational Drugs, 2019, 28, 569-572.	1.9	19
17	Target engagement in an alzheimer trial: Crenezumab lowers amyloid Î² oligomers in cerebrospinal fluid. Annals of Neurology, 2019, 86, 215-224.	2.8	70
18	Vascular Dysfunction in Alzheimerâ€™s Disease: A Prelude to the Pathological Process or a Consequence of It?. Journal of Clinical Medicine, 2019, 8, 651.	1.0	131

#	Article	IF	Citations
19	Intravenous Immunoglobulin for Patients With Alzheimerâ€™s Disease: A Systematic Review and Meta-Analysis. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 281-289.	0.9	10
20	The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics. Current Opinion in Pharmacology, 2019, 44, 62-75.	1.7	8
21	Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology, 2019, , .	0.8	6
22	The Role of Biomarkers in Alzheimerâ€™s Disease Drug Development. Advances in Experimental Medicine and Biology, 2019, 1118, 29-61.	0.8	84
23	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric AÎ². Alzheimer's Research and Therapy, 2019, 11, 97.	3.0	22
24	Gantenerumab reduces amyloid-Î² plaques in patients with prodromal to moderate Alzheimerâ€™s disease: a PET substudy interim analysis. Alzheimer's Research and Therapy, 2019, 11, 101.	3.0	131
25	A critical appraisal of amyloid-Î²-targeting therapies for AlzheimerÂdisease. Nature Reviews Neurology, 2019, 15, 73-88.	4.9	666
26	Implications of Successful Symptomatic Treatment in Parkinsonâ€™s Disease for Therapeutic Strategies of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 922-930.	1.7	6
27	Treating Alzheimer's disease by targeting iron. British Journal of Pharmacology, 2019, 176, 3622-3635.	2.7	71
28	Bad news and good news in AD, and how to reconcile them. Nature Reviews Neurology, 2019, 15, 61-62.	4.9	35
29	Alzheimerâ€™s Disease and Dementia. , 2019, , 25-82.		2
30	Rationale for the development of an Alzheimerâ€™s disease vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 645-653.	1.4	16
31	The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer's and Dementia, 2020, 16, 1553-1560.	0.4	165
32	Cerebral amyloid angiopathy and Alzheimer disease â€" one peptide, two pathways. Nature Reviews Neurology, 2020, 16, 30-42.	4.9	407
33	Status and future directions of clinical trials in Alzheimer's disease. International Review of Neurobiology, 2020, 154, 3-50.	0.9	29
34	Alzheimer's disease: Recent treatment strategies. European Journal of Pharmacology, 2020, 887, 173554.	1.7	300
35	Discontinued disease-modifying therapies for Alzheimerâ€™s disease: status and future perspectives. Expert Opinion on Investigational Drugs, 2020, 29, 919-933.	1.9	22
36	Alzheimer's disease drug development pipeline: 2020. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12050.	1.8	353

#	Article	IF	Citations
37	Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimerâ€™s Disease Treated with Escalating Doses for up to 133ÂWeeks. Journal of Alzheimer's Disease, 2020, 76, 967-979.	1.2	36
38	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8651.	1.8	23
39	Modeling neurodegenerative diseases with cerebral organoids and other three-dimensional culture systems: focus on Alzheimerâ€™s disease. Stem Cell Reviews and Reports, 2022, 18, 696-717.	1.7	28
41	Computational Investigation of Gantenerumab and Crenezumab Recognition of AÎ² Fibrils in Alzheimerâ€™s Disease Brain Tissue. ACS Chemical Neuroscience, 2020, 11, 3233-3244.	1.7	12
42	Amyloidosis increase is not attenuated by long-term calorie restriction or related to neuron density in the prefrontal cortex of extremely aged rhesus macaques. GeroScience, 2020, 42, 1733-1749.	2.1	17
43	Revisiting the Amyloid Cascade Hypothesis: From Anti-AÎ² Therapeutics to Auspicious New Ways for Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 5858.	1.8	79
44	Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. Dementia and Geriatric Cognitive Disorders, 2020, 49, 334-348.	0.7	34
45	An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimerâ€™s disease. Science Translational Medicine, 2020, 12, .	5.8	77
47	Nâ€terminal heterogeneity of parenchymal and vascular amyloidâ€Î² deposits in Alzheimerâ€™s disease. Neuropathology and Applied Neurobiology, 2020, 46, 673-685.	1.8	20
48	AMBAR, an Encouraging Alzheimer's Trial That Raises Questions. Frontiers in Neurology, 2020, 11, 459.	1.1	11
49	Molecular Pathogenesis and Interventional Strategies for Alzheimerâ€™s Disease: Promises and Pitfalls. ACS Pharmacology and Translational Science, 2020, 3, 472-488.	2.5	21
50	The Hypothesis That Refuses to Die. , 2020, , 95-104.		0
52	The Shaky Six and the â€œSecond Realityâ€• , 2020, , 1-10.		0
53	Pieces of a Puzzle?. , 2020, , 11-24.		0
54	Disease â€œRedefinitionâ€• A Tough Pill to Swallow. , 2020, , 25-32.		0
55	Disease Subtypes: The Promise and the Fallacy. , 2020, , 33-40.		2
56	Protein Paradox. , 2020, , 41-56.		0
57	The Fault in Our Models. , 2020, , 57-70.		0

#	Article	IF	Citations
58	Biomarkers: The Promise and the Fallacy. , 2020, , 71-80.		0
59	Lessons from Oncology. , 2020, , 81-86.		0
60	Symptomatic vs. Disease-Modifying Therapies. , 2020, , 87-94.		3
61	Our Living Dissonance. , 2020, , 105-110.		0
62	The Scientific and Lay Narratives. , 2020, , 111-124.		0
63	Challenges Viewed from Afar. , 2020, , 125-132.		0
64	The Moonshot: Population-Based Studies of Aging. , 2020, , 133-138.		0
65	Predictions for the 2020s and Beyond. , 2020, , 139-147.		0
66	Note Added at Press Time â€“ Reviving LOF. , 2020, , 150-150.		0
69	Secretion of proteins and antibody fragments from transiently transfected endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 2020, 24, 8772-8778.	1.6	9
70	Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 16.	3.0	31
71	Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain. Frontiers in Aging Neuroscience, 2019, 11, 373.	1.7	220
72	What works and what does not work in Alzheimerâ€™s disease? From interventions on risk factors to antiâ€amyloid trials. Journal of Neurochemistry, 2020, 155, 120-136.	2.1	26
73	Passive antiamyloid immunotherapy for Alzheimer's disease. Current Opinion in Psychiatry, 2020, 33, 284-291.	3.1	40
74	Clinical Trials in Alzheimerâ€™s Disease: A Hurdle in the Path of Remedy. International Journal of Alzheimer's Disease, 2020, 2020, 1-13.	1.1	62
75	Pharmacotherapy of Alzheimerâ€™s Disease: Seeking Clarity in a Time of Uncertainty. Frontiers in Pharmacology, 2020, 11, 261.	1.6	48
76	Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid-Î² accumulation and improves cognition in APP/PS1 mice. Brain, Behavior, and Immunity, 2021, 91, 128-141.	2.0	16
77	Is Î³-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. Journal of Biological Chemistry, 2021, 296, 100489.	1.6	32

#	Article	IF	Citations
78	Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals, 2021, 14, 92.	1.7	35
79	Immunotherapy for Alzheimerâ€™s Disease: Current Scenario and Future Perspectives. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-18.	1.5	10
80	Power and sample size for random coefficient regression models in randomized experiments with monotone missing data. Biometrical Journal, 2021, 63, 806-824.	0.6	4
81	APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Science Translational Medicine, 2021, 13, .	5.8	76
82	Alzheimer Disease Clinical Trials Targeting Amyloid. Neurologist, 2021, 26, 52-61.	0.4	19
83	An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimerâ€™s Disease Treatment?. Frontiers in Pharmacology, 2021, 12, 652455.	1.6	15
84	On the role of Brain Imaging in drug development for psychiatry. Current Clinical Pharmacology, 2021, 16, 46-71.	0.2	0
85	Molecular mechanisms of amyloid disaggregation. Journal of Advanced Research, 2022, 36, 113-132.	4.4	14
86	Insulin Resistance as a Common Link Between Current Alzheimerâ€™s Disease Hypotheses. Journal of Alzheimer's Disease, 2021, 82, 71-105.	1.2	21
87	Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?. Cells, 2021, 10, 1267.	1.8	15
88	Neurotoxic Soluble Amyloid Oligomers Drive Alzheimerâ€™s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. International Journal of Molecular Sciences, 2021, 22, 6355.	1.8	74
89	Critical Appraisal of Amyloid Lowering Agents in AD. Current Neurology and Neuroscience Reports, 2021, 21, 39.	2.0	57
90	Immunotherapies for Neurodegenerative Diseases. Frontiers in Neurology, 2021, 12, 654739.	1.1	31
91	Therapy for Alzheimerâ€™s disease: Missing targets and functional markers?. Ageing Research Reviews, 2021, 68, 101318.	5.0	34
92	Defective Autophagy and Mitophagy in Alzheimerâ€™s Disease: Mechanisms and Translational Implications. Molecular Neurobiology, 2021, 58, 5289-5302.	1.9	17
93	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience, 2021, 19, 423-433.	0.9	11
94	Safety, Tolerability, and Pharmacokinetics of Highâ€Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2021, 110, 1337-1348.	2.3	6
95	Soluble Amyloid-Î² Consumption in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, 1403-1415.	1.2	31

#	Article	IF	Citations
96	Diagnosis and Treatment of Alzheimerâ€™s Disease:. Delaware Journal of Public Health, 2021, 7, 74-85.	0.2	8
97	The Rhesus Macaque as a Translational Model for Neurodegeneration and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 734173.	1.7	15
98	GPR40 Agonist Ameliorate Pathological Neuroinflammation of Alzheimerâ€™s Disease via the Modulation of Gut Microbiota and Immune System, a Mini-Review. Neurotoxicity Research, 2021, 39, 2175-2185.	1.3	3
99	Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease. JAMA Network Open, 2021, 4, e2124124.	2.8	30
100	Amyloid-Î² and Î±-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. Frontiers in Neuroscience, 2021, 15, 733857.	1.4	25
101	Resting-state functional magnetic resonance imaging in a randomized clinical trial for Alzheimer's disease. NeuroImage Reports, 2021, 1, 100055.	0.5	1
102	The Ups and Downs of Amyloid in Alzheimerâ€™s. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-4.	1.5	2
103	Alzheimer's Disease Pharmacology. , 2021, , .		1
106	Effector function of anti-pyroglutamate-3 AÎ² antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimerâ€™s-like mice. Alzheimer's Research and Therapy, 2020, 12, 12.	3.0	26
107	THE FUTURE OF ANTI-AMYLOID TRIALS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6.	1.5	34
108	Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice. Medical Research Archives, 2020, 8, .	0.1	14
109	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	0.9	12
110	Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies. Current Drug Targets, 2020, 21, 148-166.	1.0	14
111	Therapeutic Strategies Targeting Amyloid-Î² in Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 418-452.	0.7	88
112	Mechanistic Modeling of Soluble AÎ² Dynamics and Target Engagement in the Brain by Anti-AÎ² mAbs in Alzheimerâ€™s Disease. Current Alzheimer Research, 2020, 17, 393-406.	0.7	6
113	Alzheimerâ€™s disease clinical trial update 2019â€“2021. Journal of Neurology, 2022, 269, 1038-1051.	1.8	39
114	Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 10766.	1.8	23
115	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0

#	Article	IF	Citations
117	Immunotherapy Targeting Amyloid-ÃŸ Peptides in Alzheimerâ€™s Disease. , 0, , 23-49.		3
120	Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 457-472.	1.2	6
121	Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurology, 2022, 79, 13.	4.5	244
122	Mechanistic and therapeutic implications of EphAâ€4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5532-5546.	1.2	8
123	The molecular mechanism, targets, and novel molecules in the treatment of Alzheimerâ€™s disease. Bioorganic Chemistry, 2022, 119, 105562.	2.0	26
124	Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimerâ€™s Disease Treated with Anti-Amyloid Beta Therapy. journal of prevention of Alzheimer's disease, The, 2022, 9, 211-220.	1.5	25
125	Amyloid-Related Imaging Abnormalities and Î²-Amyloidâ€“Targeting Antibodies. JAMA Neurology, 2022, 79, 291.	4.5	43
126	Role of prolineâ€rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5442-5452.	1.2	2
127	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5516-5531.	1.2	13
128	New Perspectives for Treatment in Alzheimerâ€™s Disease. , 2022, , 199-225.		0
129	Safety and Efficacy of Monoclonal Antibodies for Alzheimerâ€™s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials. Journal of Alzheimer's Disease, 2022, 87, 101-129.	1.2	31
130	Role of Pharmacogenomics in Individualizing Treatment for Alzheimerâ€™s Disease. CNS Drugs, 2022, 36, 365-376.	2.7	6
131	Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes. CNS and Neurological Disorders - Drug Targets, 2021, 21, .	0.8	0
132	Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid-Î² peptides 1â€“42 and 1â€“40 in CSF. Clinical Chemistry and Laboratory Medicine, 2022, 60, 198-206.	1.4	2
133	Impact of Anti-amyloid-Î² Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimerâ€™s Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging Neuroscience, 2022, 14, 870517.	1.7	91
134	Amyloid-beta targeted therapeutic approaches for Alzheimerâ€™s disease: long road ahead. Current Drug Targets, 2022, 23, .	1.0	6
135	DNA Damage Increases Secreted AÎ²40 and AÎ²42 in Neuronal Progenitor Cells: Relevance to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 88, 177-190.	1.2	5
136	Amyloid-Î² Oligomers: Multiple Moving Targets. Biophysica, 2022, 2, 91-110.	0.6	17

#	Article	IF	Citations
137	Anti-Amyloid-Î² Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2022, 22, .	1.1	0
138	Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	15
139	A Historical Review of Brain Drug Delivery. Pharmaceutics, 2022, 14, 1283.	2.0	65
140	Pharmacotherapy for Alzheimerâ€™s disease: whatâ€™s new on the horizon?. Expert Opinion on Pharmacotherapy, 0, , 1-19.	0.9	1
141	Are we ready to use anti-amyloid therapy in Alzheimer's disease?. Arquivos De Neuro-Psiquiatria, 2022, 80, 15-23.	0.3	2
142	Based on molecular structures: Amyloid-Î² generation, clearance, toxicity and therapeutic strategies. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	6
143	Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Antiâ€“Î²-Amyloid Immunotherapy. Neurology, 2022, 99, .	1.5	13
144	Immunotherapies for Alzheimerâ€™s Diseaseâ€”A Review. Vaccines, 2022, 10, 1527.	2.1	12
145	The Immune System as a Therapeutic Target for Alzheimerâ€™s Disease. Life, 2022, 12, 1440.	1.1	6
146	Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease. JAMA Neurology, 2022, 79, 1113.	4.5	57
147	Lecanemab, Aducanumab, and Gantenerumab â€” Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics, 2023, 20, 195-206.	2.1	104
148	Generation of ‹sup›13‹/sup›C-Labeled Inositol and Inositol Phosphates by Stable Isotope Labeling Cell Culture for Quantitative Metabolomics. Analytical Chemistry, 2022, 94, 15332-15340.	3.2	0
149	Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report. Radiology Case Reports, 2023, 18, 275-279.	0.2	3
150	Engineering antibody and protein therapeutics to cross the bloodâ€“brain barrier. Antibody Therapeutics, 2022, 5, 311-331.	1.2	4
151	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders. Molecular Neurobiology, 2023, 60, 1690-1720.	1.9	11
152	Therapeutic antiâ€amyloid Î² antibodies cause neuronal disturbances. Alzheimer's and Dementia, 2023, 19, 2479-2496.	0.4	8
153	Neuronal deletion of nSMase2 reduces the production of AÎ² and directly protects neurons. Neurobiology of Disease, 2023, 177, 105987.	2.1	0
154	Links between COVID-19 and Parkinsonâ€™s disease/Alzheimerâ€™s disease: reciprocal impacts, medical care strategies and underlying mechanisms. Translational Neurodegeneration, 2023, 12, .	3.6	15

#	Article	IF	Citations
155	Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease. Frontiers in Neuroscience, 0, 17, .	1.4	1
156	Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. Alzheimer's Research and Therapy, 2023, 15, .	3.0	4
157	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. Neuropharmacology, 2023, 229, 109478.	2.0	10
158	Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 143-154.	1.0	6
159	In vivo characterization of cerebrovascular impairment induced by amyloid Î² peptide overload in glymphatic clearance system using swept-source optical coherence tomography. Neurophotonics, 2023, 10, .	1.7	2
160	Disease-modifying vs symptomatic treatments: Splitting over lumping. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 187-209.	1.0	5
161	Lessons from antiamyloid-Î² immunotherapies in Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 267-291.	1.0	7
162	Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease. Neurology and Therapy, 2023, 12, 571-595.	1.4	2
163	Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-Ã-vis placebo in mild or moderate Alzheimer's disease. Frontiers in Neurology, 0, 14, .	1.1	1
171	Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update. Neurotherapeutics, 2023, 20, 914-931.	2.1	22
180	Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimerâ€™s Disease. BioDrugs, 2024, 38, 5-22.	2.2	5
185	Anti-amyloid Antibody Therapies for Alzheimerâ€™s Disease. Nuclear Medicine and Molecular Imaging, 0, , .	0.6	0